Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 593 of 6351
-
New combo aims to tackle tough breast cancer
Disease control Not yet recruitingThis is a multicenter, open-label, randomized phase II trial evaluating the efficacy and safety of sacituzumab govitecan plus toripalimab versus toripalimab plus nab-paclitaxel in patients with previously untreated, unresectable, locally advanced or metastatic triple-negative bre…
Phase 2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 26, 2026 15:18 UTC
-
AI reads chest x-rays to catch TB earlier in china
Diagnosis Recruiting nowThe global incidence rate and mortality of tuberculosis (TB) pose a challenge to achieving the goals set out in the tuberculosis eradication strategy and the SDGs by 2030. At present, timely and accessible early detection methods for tuberculosis are still a major obstacle. In th…
Sponsor: Xuelin Yang • Aim: Diagnosis
Last updated Jun 27, 2026 08:07 UTC
-
Can a cholesterol drug help immunotherapy fight colorectal cancer?
Disease control Recruiting nowMetastatic colorectal cancer with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) molecular phenotypes could significantly benefit from immune checkpoint inhibitor therapy, ushering in the MSI era of immunotherapy for colorectal cancer. However, MSI-H/…
Phase 2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New cocktail of drugs aims to tackle tough colorectal cancer
Disease control Recruiting nowThe ONTOP study is a prospective, single-arm, open-label phase II clinical trial. A total of 32 patients with advanced MSS/pMMR colorectal cancer who have failed first-line treatment will receive second-line standard treatment combined with Ongericimab and toripalimab. Among them…
Phase 2 • Sponsor: Shanghai Pudong Hospital • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Smartphone app aims to boost recovery from opioid addiction and depression
Disease control Recruiting nowThe sequential trial compares recovery and mHealth engagement outcomes among Black participants who participated in the mHealth intervention uMAT-R or uMAT-R + enhanced community engagement. The mHealth intervention seeks to support people in various stages of recovery who are al…
Phase 2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New hope for elderly leukemia patients: study tests gentler chemo combo
Disease control Recruiting nowThis study is a multicenter, randomized, controlled phase III clinical trial aimed at comparing the efficacy of two induction chemotherapy regimens-VA (Venetoclax + Azacitidine) and D/IA (Daunorubicin/Idarubicin + Cytarabine)-in elderly patients (aged 55-75) with acute myeloid le…
Phase 3 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New cocktail of drugs targets Hard-to-Treat bile duct cancer
Disease control Not yet recruitingThis trial is a single-arm exploratory phase II clinical study initiated by the investigator. Subjects who met the research criteria were screened and enrolled to receive the treatment regimen of disitamab vedotin combined with lenvatinib and PD-1 inhibitor. During the treatment…
Phase 2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 26, 2026 14:45 UTC
-
New drug duo aims to save bladders in HER2-positive cancer patients
Disease control Not yet recruitingThis study aims to evaluate the efficacy of disitamab vedotin combined with toripalimab as a bladder-preserving treatment combination in patients with HER2 positive locally advanced MIBC, including one year bladder-intact DFS (BI-DFS) and safety.
Phase 2 • Sponsor: Renmin Hospital of Wuhan University • Aim: Disease control
Last updated Jun 26, 2026 13:16 UTC
-
Timing is everything: new trial tests early vs. delayed surgery for spinal cord injury
Disease control Recruiting nowTo compare the outcome of early versus delayed surgical decompression among patients presenting with traumatic spinal cord injury in a tertiary care hospital.
Sponsor: Fauji Foundation Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Radiation and immunotherapy combo shows promise for tough colon cancers
Disease control Recruiting nowMost colorectal cancers are microsatellite stable (MSS) or mismatch repair-proficient (pMMR) subtypes, which show limited efficacy to PD-1 inhibitors. Radiotherapy can enhance the release of tumor-associated antigens, thereby improving the responsiveness of pMMR/MSS colorectal ca…
Phase 2 • Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New online tool aims to stop postpartum depression before it starts
Prevention By invitation onlyThe goal of this randomized controlled study is to evaluate whether an online intervention that combines psychoeducation and affective cognitive training can help prevent postpartum depression in pregnant women and co-parents who have been identified as having risk factors for po…
Sponsor: Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital • Aim: Prevention
Last updated Jun 27, 2026 08:06 UTC
-
AI boosts breast cancer detection in ultrasound study
Diagnosis CompletedThis is a retrospective, fully-crossed, multi-reader, multi-case (MRMC) study to evaluate the effectiveness of 'CadAI-B Dx' (CadAI-B) for decision support in breast ultrasound. The study compares the diagnostic performance of readers interpreting breast ultrasound images with and…
Sponsor: BeamWorks Inc. • Aim: Diagnosis
Last updated Jun 27, 2026 08:04 UTC
-
New hope for duchenne: experimental drug ENTR-601-45 enters human trials
Disease control Recruiting nowThis is a study of the investigational medicine ENTR-601-45 in participants who have Duchenne muscular dystrophy (DMD), a rare genetic condition. The researchers want to: Test how safe ENTR-601-45 is, learn about any side effects, and look at the potential positive effects of ENT…
Phase 1/2 • Sponsor: Entrada Therapeutics, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a new blood test spot colorectal cancer return earlier?
Diagnosis Recruiting nowThis clinical trial compares minimal residual disease (MRD) testing with the Haystack blood test (assay) to the Signatera® assay for the early detection of the cancer returning (cancer recurrence) in patients with stage II-IV colorectal cancer (CRC) that can be removed by surgery…
Sponsor: City of Hope Medical Center • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC
-
New drug shows promise for Tough-to-Treat stomach cancer
Disease control OngoingThe purpose of this study is to measure the efficacy and safety of AZD0901 monotherapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2.
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for tough myeloma: drug plus radiation trial launches
Disease control Recruiting nowThis phase I/II trial tests the safety and effectiveness of extramedullary disease (EMD)-directed external beam radiation therapy (EBRT) in combination with talquetamab for the treatment of multiple myeloma patients with extramedullary disease. Extramedullary disease in multiple …
Phase 1/2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 26, 2026 18:48 UTC
-
New drug shows promise in lung cancer fight
Disease control Recruiting nowThis is an open-label, multicenter, phase II study. The purpose of this study is to evaluate the safety, tolerability and preliminary anti-tumor activity of SKB518 in patients with lung cancer. Eligible subjects will receive SKB518 monotherapy, until radiographic disease progress…
Phase 2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New combo therapy aims to halt brain tumors in lung cancer patients
Disease control Recruiting nowThis study is a multicenter, randomized, prospective Phase III study to evaluate the efficacy and safety of anlotinib plus whole-brain radiotherapy (WBRT) compared with WBRT alone in small cell lung cancer (SCLC) patients with brain metastases. Additionally, by investigating the …
Phase 3 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Immunotherapy plus chemo and radiation: new hope for lung cancer?
Disease control Recruiting nowTo evaluate the Efficacy and Safety of the Combination of Sintilimab With Platinum-doublet Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients
Phase 2 • Sponsor: The Third Xiangya Hospital of Central South University • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New combo therapy aims to stall rare gut tumors
Disease control Recruiting nowThere is limited evidence regarding the benefit of adding somatostatin analogs to molecular targeted agents for well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) with poor prognostic factors. This trial is conducted to evaluate sirolimus for injection (a…
Phase 2/3 • Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC